{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:36:51Z","timestamp":1769974611705,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["study number: 202067"],"award-info":[{"award-number":["study number: 202067"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12325-018-0771-4","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T09:59:37Z","timestamp":1536227977000},"page":"1626-1638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid\/Long-Acting \u03b22-Agonist Therapy: An Integrated Post Hoc Analysis"],"prefix":"10.1007","volume":"35","author":[{"given":"Ian P.","family":"Naya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Tombs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Compton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"771_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2018. http:\/\/goldcopd.org\/wp-content\/uploads\/2017\/11\/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed Jan 23, 2018."},{"key":"771_CR2","unstructured":"World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD) fact sheet. Updated November 2017. http:\/\/www.who.int\/mediacentre\/factsheets\/fs315\/en\/. Accessed Nov 16, 2017."},{"issue":"1","key":"771_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/resp.12660","volume":"21","author":"JL Lopez-Campos","year":"2016","unstructured":"Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14\u201323.","journal-title":"Respirology"},{"issue":"1","key":"771_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1183\/09031936.00194610","volume":"39","author":"CR Jenkins","year":"2012","unstructured":"Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38\u201345.","journal-title":"Eur Respir J"},{"key":"771_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12890-015-0077-0","volume":"15","author":"CR Jenkins","year":"2015","unstructured":"Jenkins CR, Postma DS, Anzueto AR, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:97.","journal-title":"BMC Pulm Med."},{"issue":"1","key":"771_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/13696998.2016.1223085","volume":"20","author":"YS Punekar","year":"2017","unstructured":"Punekar YS, Naya I, Small M, et al. Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study. J Med Econ. 2017;20(1):28\u201336.","journal-title":"J Med Econ."},{"issue":"1","key":"771_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s41030-016-0011-5","volume":"2","author":"YS Punekar","year":"2016","unstructured":"Punekar YS, Mullerova H, Small M, et al. Prevalence and burden of dyspnoea among patients with chronic obstructive pulmonary disease in five European countries. Pulm Ther. 2016;2(1):59\u201372.","journal-title":"Pulm Ther."},{"issue":"1","key":"771_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12931-017-0566-1","volume":"18","author":"YS Punekar","year":"2017","unstructured":"Punekar YS, Sharma S, Pahwa A, Takyar J, Naya I, Jones PW. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18(1):86.","journal-title":"Respir Res"},{"issue":"1","key":"771_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1378\/chest.125.1.249","volume":"125","author":"DP Tashkin","year":"2004","unstructured":"Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125(1):249\u201359.","journal-title":"Chest"},{"issue":"2","key":"771_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1183\/20734735.014813","volume":"10","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10(2):111\u201320.","journal-title":"Breathe."},{"issue":"1","key":"771_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1378\/chest.11-0038","volume":"141","author":"PM Short","year":"2012","unstructured":"Short PM, Williamson PA, Elder DHJ, Lipworth SIW, Schembri S, Lipworth BJ. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD. Chest. 2012;141(1):81\u20136.","journal-title":"Chest"},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/COPD.S122013","volume":"12","author":"JC Simeone","year":"2017","unstructured":"Simeone JC, Luthra R, Kaila S, et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2017;12:73\u201383.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2466-11-61","volume":"11","author":"CM Kozma","year":"2011","unstructured":"Kozma CM, Paris AL, Plauschinat CA, Slaton T, Mackowiak JI. Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study. BMC Pulm Med. 2011;11:61.","journal-title":"BMC Pulm Med."},{"issue":"15","key":"771_CR14","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/archinternmed.2009.233","volume":"169","author":"TA Lee","year":"2009","unstructured":"Lee TA, Wilke C, Joo M, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2009;169(15):1403\u201310.","journal-title":"Arch Intern Med"},{"issue":"15","key":"771_CR15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543\u201354.","journal-title":"N Engl J Med"},{"issue":"8","key":"771_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775\u201389.","journal-title":"N Engl J Med"},{"issue":"6","key":"771_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/thoraxjnl-2014-206670","volume":"70","author":"PA Frith","year":"2015","unstructured":"Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol\/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015;70(6):519\u201327.","journal-title":"Thorax"},{"key":"771_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s41030-016-0012-4","volume":"2","author":"TM Siler","year":"2016","unstructured":"Siler TM, Kerwin E, Tombs L, Fahy WA, Naya I. Triple therapy of umeclidinium\u2009+\u2009inhaled corticosteroids\/long-acting beta2 agonists for patients with COPD: pooled results of randomized placebo-controlled trials. Pulm Ther. 2016;2:43\u201358.","journal-title":"Pulm Ther."},{"issue":"4","key":"771_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","volume":"196","author":"DA Lipson","year":"2017","unstructured":"Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438\u201346.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10048","key":"771_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963\u201373.","journal-title":"Lancet"},{"key":"771_CR21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/COPD.S133307","volume":"12","author":"AR Anzueto","year":"2017","unstructured":"Anzueto AR, Vogelmeier CF, Kostikas K, et al. The effect of indacaterol\/glycopyrronium versus tiotropium or salmeterol\/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325\u201337.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"771_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/COPD.S101612","volume":"11","author":"D Singh","year":"2016","unstructured":"Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium\/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413\u201324.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"issue":"1","key":"771_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12931-017-0583-0","volume":"18","author":"D Singh","year":"2017","unstructured":"Singh D, D\u2019Urzo AD, Chuecos F, Munoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium\/formoterol. Respir Res. 2017;18(1):106.","journal-title":"Respir Res"},{"issue":"1","key":"771_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15412555.2015.1034256","volume":"13","author":"TM Siler","year":"2016","unstructured":"Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and safety of umeclidinium added to fluticasone propionate\/salmeterol in patients with COPD: results of two randomized, double-blind studies. Chron Obstruct Pulmon Dis. 2016;13(1):1\u201310.","journal-title":"COPD."},{"issue":"9","key":"771_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.rmed.2015.06.006","volume":"109","author":"TM Siler","year":"2015","unstructured":"Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate\/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med. 2015;109(9):1155\u201363.","journal-title":"Respir Med"},{"key":"771_CR26","unstructured":"GSK. Incruse summary of product characteristics. Updated 2017. https:\/\/www.medicines.org.uk\/emc\/medicine\/29394. Accessed Feb 2, 2018."},{"key":"771_CR27","unstructured":"GSK. Highlights of prescribing information. Updated 2017. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Incruse_Ellipta\/pdf\/INCRUSE-ELLIPTA-PI-PIL.PDF. Accessed Feb 2, 2018."},{"issue":"6","key":"771_CR28","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004;23(6):932\u201346.","journal-title":"Eur Respir J"},{"key":"771_CR29","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2016. http:\/\/goldcopd.org\/global-strategy-diagnosis-management-prevention-copd-2016\/. Accessed Nov 17, 2017."},{"issue":"2","key":"771_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1183\/09031936.04.00120603","volume":"24","author":"J Vestbo","year":"2004","unstructured":"Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J. 2004;24(2):206\u201310.","journal-title":"Eur Respir J"},{"issue":"4","key":"771_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1183\/09031936.00111707","volume":"31","author":"J Vestbo","year":"2008","unstructured":"Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869\u201373.","journal-title":"Eur Respir J"},{"issue":"Suppl 60","key":"771_CR32","first-page":"PA304","volume":"48","author":"I Naya","year":"2016","unstructured":"Naya I, Tombs L, Mullerova H, Compton C, Jones P. Long-term outcome following first clinically important deterioration in COPD. Eur Respir J. 2016;48(Suppl 60):PA304.","journal-title":"Eur Respir J."},{"key":"771_CR33","first-page":"A2717","volume":"195","author":"KF Rabe","year":"2017","unstructured":"Rabe KF, Halpin D, Martinez F, et al. Predicting long-term outcomes and future deterioration in COPD with a composite endpoint: post hoc analysis of the UPLIFT study. Am J Respir Crit Care Med. 2017;195:A2717.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 61","key":"771_CR34","first-page":"PA533","volume":"50","author":"D Singh","year":"2017","unstructured":"Singh D, Papi A, Vezzoli S, et al. CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP, Formoterol Fumarate:FF, Glycopyrronium Bromide:GB) reduces clinically important deteriorations (CID) in COPD: post hoc analysis of TRILOGY study. Eur Respir J. 2017;50(Suppl 61):PA533.","journal-title":"Eur Respir J."},{"issue":"18","key":"771_CR35","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med."},{"issue":"Suppl 61","key":"771_CR36","first-page":"PA3255","volume":"50","author":"AR Anzueto","year":"2017","unstructured":"Anzueto AR, Kostikas K, Shen S, et al. Indacaterol\/glycopyrronium reduces the risk of clinically important deterioration versus salmeterol\/fluticasone: the FLAME study. Eur Respir J. 2017;50(Suppl 61):PA3255.","journal-title":"Eur Respir J."},{"issue":"Suppl 61","key":"771_CR37","first-page":"PA3949","volume":"50","author":"D Singh","year":"2017","unstructured":"Singh D, Papi A, Vezzoli S, et al. Effect of CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP, Formoterol Fumarate:FF, Glycopyrronium Bromide:GB) on clinically important deteriorations (CID) in COPD: post hoc analysis of TRINITY study. Eur Respir J. 2017;50(Suppl 61):PA3949.","journal-title":"Eur Respir J."},{"key":"771_CR38","first-page":"A6779","volume":"193","author":"R Buhl","year":"2016","unstructured":"Buhl R, McGarvey L, Korn S, et al. Benefits of tiotropium\u2009+\u2009olodaterol over tiotropium at delaying clinically significant events in patients with COPD classified as GOLD B. Am J Respir Crit Care Med. 2016;193:A6779.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 61","key":"771_CR39","first-page":"PA3248","volume":"50","author":"I Naya","year":"2017","unstructured":"Naya I, Barnacle H, Birk R, et al. Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study. Eur Respir J. 2017;50(Suppl 61):PA3248.","journal-title":"Eur Respir J."},{"issue":"2","key":"771_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","volume":"178","author":"MT Wang","year":"2018","unstructured":"Wang MT, Liou JT, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229\u201338.","journal-title":"JAMA Intern Med."},{"key":"771_CR41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/COPD.S102494","volume":"11","author":"G Feldman","year":"2016","unstructured":"Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 mug compared with tiotropium 18 mug in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719\u201330.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"issue":"11","key":"771_CR42","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1517\/14740338.2014.968550","volume":"13","author":"R Manickam","year":"2014","unstructured":"Manickam R, Asija A, Aronow WS. Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use. Expert Opin Drug Saf. 2014;13(11):1555\u201361.","journal-title":"Expert Opin Drug Saf."},{"issue":"2","key":"771_CR43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s41030-017-0048-0","volume":"3","author":"KYJ Sion","year":"2017","unstructured":"Sion KYJ, Huisman EL, Punekar YS, Naya I, Ismaila A. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting b2-agonist (LABA) combinations in COPD. Pulm Ther. 2017;3(2):297\u2013316.","journal-title":"Pulm Ther."},{"issue":"10125","key":"771_CR44","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076\u201384.","journal-title":"Lancet"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0771-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0771-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0771-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:33:07Z","timestamp":1724412787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0771-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0771-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"2 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}